MedTech Acquisition Corporation - MTACU STOCK NEWS

TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.

TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.

TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.

TriSalus Life Sciences Inc. (TLSI) reported strong financial results for Q4 2023 with revenues of $5.7 million, up 77% YoY, and full-year revenues of $18.5 million, up 49% YoY. The company achieved a gross margin of 90% in Q4 2023 and 86% for the full year. TriSalus received CMS reimbursement for its TriNav Infusion System and published real-world data showing improved therapeutic delivery to liver tumors. They obtained 510k clearance for TriNav Large and TriGuide systems, completed phase 1 trials for liver indications, and initiated a phase 1 trial for a novel pancreatic infusion technology. The company also reported operating losses of $14.1 million in Q4 and $54.2 million for the full year, with net losses of $35.5 million in Q4 and $59.0 million for the full year.

TriSalus Life Sciences Inc. (TLSI) presents new safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer and a retrospective clinical study supporting the TriNav Infusion System. The technology integrates novel delivery methods with immunotherapy for liver and pancreatic tumors, featured at the Society of Interventional Radiology Annual Scientific Meeting.

TriSalus Life Sciences Inc. (TLSI) will present data at the 2024 Society of Interventional Radiology Annual Scientific Meeting on their Pressure-Enabled Drug Delivery technology for liver and pancreatic tumors. The company aims to address challenges in delivering therapeutics to pancreas tumors by modulating pressure and flow. TLSI is committed to transforming therapeutic delivery into challenging tumors and improving outcomes in solid tumor indications.

TriSalus Life Sciences Inc. (TLSI) reports strong Q4 sales of approximately $5.7 million, representing 77% growth compared to 2022. Gross margins for Q4 and full year 2023 stand at around 90% and 86% respectively. Full year 2024 sales growth is expected to exceed 50%. The company anticipates having sufficient liquidity to fund operations into the second quarter of 2024.

TriSalus Life Sciences® Inc. announced the approval of the nonproprietary name 'nelitolimod' for its therapeutic candidate SD-101 by WHO and USAN. Nelitolimod is being studied in Phase 1/1b trials for liver and pancreatic cancers. The approval marks a significant milestone for TriSalus in its mission to improve cancer treatment outcomes.

TriSalus Life Sciences Inc. announces the publication of a study in Current Medical Research and Opinion showcasing the effectiveness of the TriNav Infusion System in treating patients with liver and pancreatic tumors. The study demonstrates TriNav's success in treating sicker patients with higher disease burden, validating previous data in a real-world setting.